Learning Objectives
Upon completion of the activity, participants should be able to:

• Discuss the limitations of A1C as a marker of diabetes control
• Explain the merits of evaluating time in range and hypoglycemic and hyperglycemic excursions and as well as A1C
• Describe how glucose monitoring devices facilitate prevention, detection, and prompt treatment of hypoglycemia
• Discuss improved patient outcomes associated with glucose monitoring as well as technological advances that have improved the ease of use of these devices

Faculty

George Grunberger, MD, FACP, FACE, Program Co-Chair
Grunberger Diabetes Institute
Bloomfield Hills, Michigan

Guillermo Umpierrez, MD, FACP, Program Co-Chair
Emory University School of Medicine
Atlanta, Georgia

Timothy Bailey, MD
Advanced Metabolic Care and Research (AMCR) Institute
Escondido, California

Richard Bergenstal, MD
International Diabetes Center (IDC)
St. Louis Park, Minnesota

Lawrence Blonde, MD, FACE, MACE
Ochsner Medical Center
New Orleans, Louisiana

Jenna Brothers, PA-C
Duke University Medical Center
Durham, North Carolina

Bruce Buckingham, MD, FACE
Stanford University School of Medicine
Palo Alto, California

Ji Hyun Chun, MPAS, PA-C, BC-ADM
OptumCare Medical Group
Orange County, California

Daniel Einhorn, MD, FACP, FACE
University of California San Diego
La Jolla, California

Wendy McLaughlin, PA-C
The Endocrinology Group
Arlington, Virginia

Anne Peters, MD, CDE
Keck School of Medicine of USC
Beverly Hills, California

Archana R. Sadhu, MD, FACE
Houston Methodist Hospital
Houston, Texas

METHOD OF PARTICIPATION / HOW TO RECEIVE CREDIT
Technical Requirements: http://www.francefoundation.com/general-requirements.html

1. There are no fees for participating in and receiving credit for this activity.
2. Review the activity objectives and CME/CE information.
3. Complete the CME/CE activity
4. Complete the online posttest. A score of at least 75% is required to successfully complete this activity. The participant may take the test until successfully passed.
5. Complete the CME/CE evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
6. Credit documentation/reporting:
   • If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download.
7. To request credit, you must complete the introduction module plus 3 case modules.

ACCREDITED PROVIDER 
This activity is provided by The France Foundation in collaboration with the American Association of Clinical Endocrinologists.            

TARGET AUDIENCE
This activity is intended for endocrinologists, primary care clinicians, physician assistants, nurse practitioners, and diabetes educators.

STATEMENT OF NEED
Despite proven benefits and advances in technology that have improved the convenience and usability of blood glucose monitors and continuous glucose monitoring (CGM) devices, these technologies remain under-utilized in the diabetes community. Among patients with type 2 diabetes, only half test their blood glucose daily, and approximately a third of patients with type 1 diabetes test their glucose fewer than 3 times daily, when the recommended frequency is 1-4 times per day for type 2 and 6-8 times per day for type 1 diabetes. In addition, only 15% of patients with type 1 diabetes and a negligible proportion of type 2 patients use a CGM device. Utilization of glucose data has not been consistent in the past, but use of personal CGM has increased over the past year, yet still varied in the clinical arena with debate on the value of measuring versus the rapid development of continuous measurement technology. However, a better understanding of the meaningful use of various glucose parameters in clinical decision-making as well as the personal use of this information by patients struggling for better diabetes control is the main goal for glucose measurement and interpretation.

ACCREDITATION STATEMENT 
The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Physicians
The France Foundation designates this enduring activity for a maximum of 3.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
Nurses who are certified by the American Nurses Credentialing Center (ANCC) may utilize activities that are certified by ACCME-accredited providers toward their requirement for certification renewal by the ANCC. A certificate of attendance will be provided by The France Foundation, an ACCME accredited provider.

DISCLOSURE POLICY
In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) and the American Association of Clinical Endocrinologists (AACE) require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF and AACE resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, TFF and AACE seek to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF and AACE are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

Planning Committee Disclosures
The following planners, reviewers, editors, staff, CME committee who control content have relevant financial relationships to disclose. 

 The following planners, reviewers, editors, staff, CME committee, who control content have no relevant financial relationships to disclose.

American Association of Clinical Endocrinologist (AACE)

• Elizabeth Lepkowski, MATD, AACE Chief Learning Officer
• Michele Lentz, AACE Chief Strategic Alliances Officer
• Beverly Hastings, AACE Live Learning Manager
• Michelle Michelotti, MHA, Director of Online Learning and Technology

American Association of Diabetes Educators (AADE)

• Nancy D’Hondt, RPh

American College of Clinical Pharmacy (ACCP)

• Daniel Aistrope, PharmD, BC-ACP

American Society of Endocrine Physician Assistants (ASEPA)/American Academy of Physician Assistants (AAPA)

• Jenna Brothers, PAC
• Wendy McLaughlin, PAC

Diabetes Patient Advocacy Coalition (DPAC)

• Stewart Perry

T1D Exchange

• Alicia McAuliffe-Fogarty

The diaTribe Foundation

• Kelly Close

The France Foundation

• Ailene Cantelmi
• Amanda Noe
• Heather Tarbox, MPH
• Eve Wilson, PhD

Faculty Disclosures-Content Creators
The faculty listed below report that they have no relevant financial relationships to disclose:

• Jenna Brothers, PA-C
• Wendy McLaughlin, PA-C

The following faculty report that they have relevant financial relationships to disclose:

Faculty Disclosures-Activity Faculty
The faculty listed below report that they have no relevant financial relationships to disclose:

• Jenna Brothers, PA-C
• Wendy McLaughlin, PA-C
• Archana R. Sadhu, MD, FACE

The following faculty report that they have relevant financial relationships to disclose:

DISCLOSURE OF UNLABELED USE
TFF and ACCE require CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF and AACE do not] recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

COMMERCIAL SUPPORT ACKNOWLEDGMENT
This activity is supported by educational grants from Abbott, AstraZeneca, Dexcom, Janssen, Mannkind, and Novo Nordisk.

DISCLAIMER
The France Foundation and The American Association of Clinical Endocrinologists this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation, The American Association of Clinical Endocrinologists, and the commercial supporter(s) assume no liability for the information herein.

COPYRIGHT INFORMATION
Copyright © 2020 The France Foundation. Any unauthorized use of any materials on the site may violate copyright, trademark, and other laws. You may view, copy, and download information or software ("Materials") found on the Site subject to the following terms, conditions, and exceptions:

• The materials are to be used solely for personal, noncommercial, informational and educational purposes. The materials are not to be modified. They are to be distributed in the format provided with the source clearly identified. The copyright information or other proprietary notices may not be removed, changed, or altered.

• Materials may not be published, uploaded, posted, transmitted (other than as set forth herein), without The France Foundation's prior written permission.

PRIVACY POLICY
The France Foundation protects the privacy of personal and other information regarding participants and educational collaborators. The France Foundation will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the ACCME.

The France Foundation maintains physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse or alteration of information that we have collected from you.

Additional information regarding The France Foundation’s Privacy Policy can be viewed at http://www.francefoundation.com/privacy.

CONTACT INFORMATION

If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.